Major Depressive Disorder clinical trials

Explore recruiting major depressive disorder clinical trials.

Recruiting major depressive disorder studies right now

Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record

Also recruiting in Europe

Major Depressive Disorder trials registered in the EU Clinical Trials Information System (CTIS). These are outside the "near me" matcher above - open a study for full details.

A Phase II, 6-week, multi-centre, randomised, double-blind (participant and investigator), placebo-controlled, dose-finding trial to evaluate the efficacy, tolerability, and safety of different doses of oral BI 1569912 as adjunctive therapy in patients with major depressive disorder

Belgium, Bulgaria, Czechia, Germany

Therapeutic exploratory (Phase II) EU CTIS Study details

NBI-1065845-MDD3024: A Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy and Safety of NBI-1065845 as Adjunctive Treatment in Subjects with Major Depressive Disorder (MDD)

Poland, Croatia, Czechia

Therapeutic confirmatory (Phase III) EU CTIS Study details

A Randomized, Double-Blind, Placebo-controlled Multicenter Study to Assess the Efficacy and Safety of Milsaperidone as Adjunctive Therapy in the Treatment of Patients with Major Depressive Disorder

Poland, Czechia, Bulgaria

Therapeutic confirmatory (Phase III) EU CTIS Study details

Reward-specific changes of cerebral dopamine synthesis in healthy volunteers and depressed patients

Austria

Therapeutic use (Phase IV) EU CTIS Study details

Multi-centre, double-blind, placebo-controlled, randomised trial to prove the efficacy and safety of Silexan® (WS®1265) in patients with a major depressive episode of mild to moderate severity

Germany, Austria

Therapeutic confirmatory (Phase III) EU CTIS Study details

A Phase 2 Double-blind, Randomised, Placebo-controlled Study to Evaluate the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of DT-101 in Adults with Major Depressive Disorder

Czechia, Bulgaria, Poland

Therapeutic exploratory (Phase II) EU CTIS Study details

Major Depressive Disorder trials by city

Major Depressive Disorder in Toronto Major Depressive Disorder in Vancouver Major Depressive Disorder in Montreal Major Depressive Disorder in Calgary Major Depressive Disorder in Edmonton Major Depressive Disorder in Ottawa Major Depressive Disorder in Winnipeg Major Depressive Disorder in Quebec City Major Depressive Disorder in Hamilton Major Depressive Disorder in Kitchener Major Depressive Disorder in London Major Depressive Disorder in Halifax Major Depressive Disorder in New York Major Depressive Disorder in Los Angeles Major Depressive Disorder in Chicago Major Depressive Disorder in Houston

Other conditions

Obesity Type 2 diabetes Type 1 diabetes Prediabetes Weight loss Metabolic syndrome High cholesterol High triglycerides High blood pressure PCOS Hypothyroidism Thyroid disease Gout Fatty liver disease (NAFLD/NASH) Heart failure Coronary artery disease Atrial fibrillation Stroke Stroke recovery Peripheral artery disease Pulmonary hypertension Deep vein thrombosis Chronic kidney disease Diabetic kidney disease